Single-domain antibody directed against complement protein C5
Target:
Complement protein C5
Target description:
The complement system plays a crucial role in immune defense. It is activated via three pathways: the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP), resulting in opsonization, chemo-attraction of immune cells and target cell lysis. Complement component C5, a 190 kDa protein consisting of two disulfide linked chains (alpha 115 kDa and beta 75 kDa), is a blood circulating protein with a key role in the complement system. During complement activation, native C5 molecules are cleaved in C5a (8 kDa) and C5b (181 kDa) by C5 convertases (C4b2bC3b and C3bBbC3b) on target surfaces. While C5a is released in the supernatant where it functions as a chemoattractant upon binding to its G protein-coupled receptor C5aR1 (CD88), C5b interacts with complement proteins C6, C7, C8, and multiple copies of C9, forming the membrane attack complex (MAC). C5 acts as a therapeutic target for inhibition of complement activation.
Source:
Recombinant bivalent single-domain antibody (Lama glama), purified from S. cerevisiae using affinity chromatography. Immunization with and phage-display selection on recombinant protein using total elution.
Product details.
Specificity:
Human C5. C5d domain. Competes with the binding of RaCI.
Formulation:
0.2 µm filtered solution in PBS. The products are equipped with a C-terminal C-Direct tag with an unpaired cysteine for directional conjugation.
Mol. Weight:
14.7 kDa
Ext. Coeff. (ε):
18575 M-1cm-1
A280 at 1g/L:
1.3
Storage:
Shipped on blue ice. Store at 4˚C or -20˚C (aliquots). Addition of 0.02% sodium azide is optional.
